Is It Time to Resist Using RECIST as a Primary Endpoint for Rare Tumor Trials?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 39141513.
- Also identified by DOI 10.1158/1078-0432.CCR-24-1628.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Epithelioid hemangioendothelioma is an ultra-rare cancer driven by YAP-CAMTA1 fusion. Based on the link of the fusion to the MEK pathway, SARC33 was performed. It is a phase 2 trial examining trametinib that missed its primary objective by RECIST but demonstrated patient-reported outcome benefits in improved pain. See related article by Schuetze et al., p. 4584.
Medical subject headings
- Response Evaluation Criteria in Solid Tumors